ストックスクリーナーアプリを入手
37.90
2.03%
-0.73
アフターアワーズ：
37.50
-0.40
-1.06%
前日終値:
$38.63
開ける：
$38.55
24時間の取引高:
1.55M
Relative Volume:
0.46
時価総額：
$10.20B
収益：
$2.17B
当期純損益:
$521.27M
株価収益率:
21.41
EPS:
1.77
ネットキャッシュフロー:
$633.79M
1週間 パフォーマンス:
+0.23%
1か月 パフォーマンス:
-17.01%
6か月 パフォーマンス:
+2.51%
1年 パフォーマンス:
+46.23%
1日の値動き範囲:
$37.71
$38.60
1週間の範囲:
$37.40
$38.85
52週間の値動き範囲:
$25.12
$49.62
Exelixis Inc Stock (EXEL) Company Profile
EXEL を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
37.90 | 10.17B | 2.17B | 521.27M | 633.79M | 1.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
388.94 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.38 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
443.64 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
677.32 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
308.63 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-08 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-06-24 | アップグレード | Stephens | Equal-Weight → Overweight |
| 2025-02-24 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2025-01-27 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2025-01-24 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2024-12-20 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-17 | ダウングレード | BofA Securities | Buy → Neutral |
| 2024-10-16 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2024-09-19 | 開始されました | UBS | Neutral |
| 2024-04-11 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2023-12-19 | 開始されました | BTIG Research | Buy |
| 2023-12-15 | 開始されました | Citigroup | Buy |
| 2023-09-26 | 開始されました | H.C. Wainwright | Buy |
| 2023-08-22 | 繰り返されました | Oppenheimer | Outperform |
| 2023-08-08 | 開始されました | SVB Securities | Market Perform |
| 2023-07-11 | 再開されました | Morgan Stanley | Equal-Weight |
| 2023-05-10 | 再開されました | Piper Sandler | Overweight |
| 2023-03-09 | 開始されました | Wells Fargo | Overweight |
| 2023-01-26 | 開始されました | Credit Suisse | Outperform |
| 2022-10-18 | 開始されました | JMP Securities | Mkt Outperform |
| 2022-06-24 | 開始されました | BMO Capital Markets | Outperform |
| 2021-11-19 | 開始されました | Piper Sandler | Overweight |
| 2021-11-03 | 再開されました | Jefferies | Buy |
| 2021-10-07 | 開始されました | Jefferies | Buy |
| 2021-08-06 | 繰り返されました | H.C. Wainwright | Buy |
| 2021-06-15 | 開始されました | H.C. Wainwright | Buy |
| 2021-05-18 | 再開されました | Goldman | Sell |
| 2021-03-31 | 開始されました | Credit Suisse | Outperform |
| 2021-03-12 | 開始されました | Wolfe Research | Outperform |
| 2020-03-04 | 開始されました | Barclays | Overweight |
| 2020-01-13 | 開始されました | SunTrust | Buy |
| 2019-11-13 | 開始されました | BofA/Merrill | Buy |
| 2019-03-18 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2018-09-17 | 開始されました | Goldman | Neutral |
| 2018-09-10 | 開始されました | Morgan Stanley | Underweight |
| 2018-05-11 | 繰り返されました | Needham | Buy |
| 2017-10-17 | 繰り返されました | Needham | Buy |
| 2017-10-17 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2017-10-16 | 繰り返されました | SunTrust | Buy |
| 2017-09-22 | ダウングレード | Leerink Partners | Outperform → Mkt Perform |
| 2017-09-15 | 開始されました | RBC Capital Mkts | Outperform |
| 2017-09-12 | 繰り返されました | Needham | Buy |
| 2017-07-14 | 開始されました | SunTrust | Buy |
| 2017-03-31 | 開始されました | Needham | Buy |
| 2017-03-16 | 開始されました | Oppenheimer | Perform |
| 2017-02-28 | ダウングレード | Stifel | Buy → Hold |
| 2016-11-03 | 開始されました | Deutsche Bank | Buy |
| 2016-10-10 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2016-09-15 | 繰り返されました | Stifel | Buy |
すべてを表示
Exelixis Inc (EXEL) 最新ニュース
Exelixis (EXEL) Tumbles 16.8% as Q2 Earnings Disappoint - MSN
How to manage a losing position in Exelixis Inc.2025 Top Gainers & Stepwise Trade Signal Implementation - Newser
Developing predictive dashboards with Exelixis Inc. dataWeekly Volume Report & High Conviction Buy Zone Picks - Newser
Will Exelixis Inc. stock go up soonQuarterly Performance Summary & Daily Volume Surge Signals - Newser
Exelixis Inc. Flashes Rebound Signal in Oversold ConditionJuly 2025 Outlook & High Accuracy Investment Entry Signals - beatles.ru
Sector ETF performance correlation with Exelixis Inc.July 2025 Highlights & Daily Stock Trend Watchlist - Newser
When is the best time to exit Exelixis Inc.2025 Growth vs Value & Weekly Market Pulse Updates - Newser
Should you wait for a breakout in Exelixis Inc.Market Trend Report & Safe Capital Growth Tips - Newser
What candlestick patterns are forming on Exelixis Inc.Weekly Stock Analysis & Capital Efficiency Focused Ideas - Newser
Price momentum metrics for Exelixis Inc. explainedQuarterly Growth Report & Daily Entry Point Alerts - Newser
Will EXEL's Share Repurchase Program Boost Value for Investors? - sg.finance.yahoo.com
Can Exelixis Inc. Rally Enough to Break EvenJuly 2025 Opening Moves & Growth Focused Stock Reports - classian.co.kr
Is Exelixis Inc. stock forming a cup and handleBear Alert & Fast Gain Stock Trading Tips - thegnnews.com
Is Exelixis Inc. building a consolidation base2025 Big Picture & Real-Time Chart Breakout Alerts - Newser
BofA Hikes Exelixis, Inc. (EXEL) Target Amid CRC Caution - MSN
Live Scanner Shows Breakout on Exelixis Inc.Portfolio Return Summary & Weekly Breakout Opportunity Watchlist - newsimpact.co.kr
Exelixis reports Q2 rev. below consensus, net product revenues 2% lower YoY. - AInvest
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc.EXEL - FinancialContent
H.C. Wainwright Maintains Buy on Exelixis (EXEL) Despite STELLAR-305 Phase 3 Setback - MSN
Signal strength of Exelixis Inc. stock in tech scannersInflation Watch & Community Shared Stock Ideas - Newser
H.C. Wainwright Maintains Buy Rating on Exelixis Despite STELLAR-305 Phase 3 Setback - AInvest
What makes Exelixis Inc. stock price move sharplyStop Loss & Free Community Supported Trade Ideas - thegnnews.com
Did You Suffer Losses in Exelixis, Inc. (EXEL)? Contact Levi & Korsinsky About Securities Fraud Claims - ACCESS Newswire
Exelixis Q2 net product revs down 2% at $531.3mln, below consensus. - AInvest
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc.EXEL - MarketScreener
Momentum Screeners Rank Exelixis Inc. in Top 5 TodayQuarterly Market Review & Scalable Portfolio Growth Ideas - newsimpact.co.kr
Will Exelixis Inc. continue its uptrendJuly 2025 Action & Expert Curated Trade Setups - Newser
Is it too late to sell Exelixis Inc.Quarterly Growth Report & AI Forecast for Swing Trade Picks - Newser
EXEL Investor Notice: Levi & Korsinsky Investigates Exelixis, Inc. for Securities Law Violations - ACCESS Newswire
Pan-Tumor Rollover Study: Bristol-Myers Squibb, Exelixis, and Novartis Collaborate on Long-Term Cancer Treatment - AInvest
Investigation Underway: Exelixis, Inc. (EXEL)Contact Levi & Korsinsky Over Securities Law Violations - ACCESS Newswire
Exelixis Q2 2025 presentation slides: Cabozantinib franchise grows 19% YoY By Investing.com - Investing.com Canada
Statistical indicators supporting Exelixis Inc.’s strengthJuly 2025 Retail & Fast Entry High Yield Tips - Newser
Exelixis Inc. Builds Base for Possible ReboundJuly 2025 Highlights & Safe Capital Growth Plans - sundaytimes.kr
Exelixis, Inc. (EXEL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Investors in Exelixis, Inc. (EXEL) Warned of Potential Securities FraudContact Levi & Korsinsky Today - ACCESS Newswire
Ongoing Securities Investigation into Exelixis, Inc. (EXEL)Contact Levi & Korsinsky - ACCESS Newswire
Exelixis Gains 15.6% YTD: How Should You Play the Stock? - The Globe and Mail
Exelixis Inc. Rebounds From Oversold Zone — Now What2025 Stock Rankings & AI Forecast for Swing Trade Picks - mustnews.co.kr
Lost Money on Exelixis, Inc. (EXEL)? Contact Levi & Korsinsky to Protect Your Rights - ACCESS Newswire
Will Zanzalintinib Ease Out EXEL's Reliance on Cabometyx for Growth? - Yahoo Finance
PNC Financial Services Group Inc. Acquires 1,029 Shares of Exelixis, Inc. (NASDAQ:EXEL) - Defense World
Exelixis (EXEL) Price Target Lowered by HC Wainwright, Analysts Maintain Overall Positive Outlook - AInvest
Exelixis, Inc. (EXEL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
What Fibonacci levels say about Exelixis Inc. reboundWeekly Stock Movement Prediction Watchlist - Newser
Exelixis stock price target lowered to $46 at H.C. Wainwright on SCCHN trial halt - Investing.com Nigeria
Exelixis Inc (EXEL) 財務データ
収益
当期純利益
現金流量
EPS
Exelixis Inc (EXEL) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| WYSZOMIERSKI JACK L | Director |
Jun 03 '25 |
Sale |
43.09 |
7,535 |
324,683 |
358,882 |
1.34%
0.52%
大文字化:
|
ボリューム (24 時間):